This trial is active, not recruiting.

Condition peripheral vascular disease
Treatment stenting of atherosclerotic lesion(s)
Sponsor NovoStent Corporation
Start date April 2009
End date September 2010
Trial size 39 participants
Trial identifier NCT01139177, 60-00857-01


The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
stenting of atherosclerotic lesion(s) SAMBA Stent and Delivery System
Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)

Primary Outcomes

The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
time frame: through 30 days
The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5).
time frame: 3 months

Secondary Outcomes

Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5).
time frame: 12 months
Change in Rutherford Classification compared to pre-implant.
time frame: 12 months
Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5).
time frame: 12 months
Stent Fractures.
time frame: 12 months

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: Screening 1. Patient must be ≥ 21 years of age with life expectancy > 1 year. 2. Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain). 3. Patient must be a suitable candidate for PTA and stenting. 4. Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements. 5. The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site. Pre-Intervention 1. Target lesion has ≥ 50% stenosis as demonstrated angiographically. 2. Lesion length ≤ 15 cm. 3. Reference vessel diameter of 5 to 6 mm. 4. Patient has at least 1 vessel run-off prior to treatment. Exclusion Criteria: Screening 1. The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.) 2. Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure. 3. Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent. 4. Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy. 5. Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.). 6. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment. 7. Patient is currently participating in another investigational drug or device study. Pre-Intervention 1. Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%). 2. Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%) 3. Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s). 4. Lack of 1 cm of healthy vessel proximal to proximal target 5. Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal). 6. Inability to cross the lesion with a guidewire. 7. More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting. 8. Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).

Additional Information

Official title SAMBA EU Femoropopliteal Trial
Principal investigator Dierk Scheinert, MD
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by NovoStent Corporation.